2/7/2014 6:48:15 AM
Shire’s $4.2 billion acquisition of ViroPharma last month generated a huge payday for ViroPharma’s top executives and board members. Documents filed with the Securities & Exchange Commission show the Exton, Pa., biopharmaceutical company’s top executive officers and seven board members held stock, vested and unvested options and performance share units valued at more than $260 million. In fact, it's uncertain which executives stayed with the merged company, as a Shire spokesperson declined commenting on that.
Help employers find you! Check out all the jobs and post your resume.
comments powered by